RUTW241119C2355000
- 0.30
- -1.39-82.25%
Russell 2000 Index Newsroom
IHeartMedia Analyst Ratings
Six Flags Entertainment Analyst Ratings
Archer Aviation Analyst Ratings
Energizer Hldgs Q4 2024 Adj EPS $1.22 Beats $1.17 Estimate, Sales $805.70M Miss $806.44M Estimate
Needham Initiates Coverage On Joby Aviation With Buy Rating, Announces Price Target of $8
Pfizer, Arvinas Delay Late-stage Trial for Breast Cancer Therapy
Joby Aviation Analyst Ratings
TDC NET Selects VIAVI's NITRO AIOps For Advanced, Automated End-To-End Network Monitoring Across Complex Domain
Esperion Therapeutics Analyst Ratings
Protagonist Therapeutics Analyst Ratings
AeroVironment Agrees To Acquire BlueHalo In An All-stock Transaction With An Enterprise Value Of $4.1B
Why Symbotic Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket
HC Wainwright & Co. Reiterates Buy on Bit Digital, Maintains $7 Price Target
Bit Digital Analyst Ratings
Breaking News | ZETA surged over 4% in pre-market trading after closing up over 11% yesterday, following institutional short-selling, the CEO and other executives increased their shareholding.
Zeta Global, which had previously been targeted by short-selling institutions, saw its CEO and senior leadership team, along with board of directors members, complete shareholding increases, resulting in a significant pre-market rise.
Daily options tracking | New auditors have come on board! The super micro computer surged over 30% before trading, with yesterday's call ratio skyrocketing to 65%; DJT is reported to be in talks to acquire the trading platform Bakkt, with multiple call op
Microstrategy, known as a "bitcoin hold positions whale," rose nearly 13% yesterday, with options volume reaching 0.43 million contracts, and the call ratio increasing to 58.4%; the highest volume for calls expiring this Friday with a strike price of $400 was 0.017 million contracts, an increase of over 80%.
Bernstein Downgrades Sabre to Underperform, Announces $3 Price Target
Sabre Analyst Ratings
Needham Reiterates Hold on Fate Therapeutics
Fate Therapeutics Analyst Ratings